A bispecific antibody targeting CLDN18.2 and 4-1BB induces potent anti-tumor efficacy with an extraordinary safety profile

被引：0
|
作者：
Chen, Junying [1 ]
Huang, Weifeng [2 ]
Liang, Zhiquan [1 ]
Miao, Xiaoniu [1 ]
Peng, Shaogang [2 ]
Wang, Chao [1 ]
Dong, Tiantian [1 ]
Tsun, Andy [1 ]
Luo, Yi [1 ]
机构：
[1] Biotheus Inc, Zhuhai, Peoples R China
[2] Biotheus Suzhou Co Ltd, Suzhou, Peoples R China
来源：
CANCER RESEARCH | 2022年 / 82卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5555
引用
收藏
页数：2
相关论文
共 50 条
  • [1] OriA362: A promising CLDN18.2/4-1BB bispecific antibody for targeting pancreatic and gastric cancers with high efficacy and safety profile
    Yang, S.
    Wu, K.
    Shi, Z.
    Wang, H.
    Li, X.
    He, X.
    ANNALS OF ONCOLOGY, 2024, 35 : S157 - S157
  • [2] Safety and Pharmacokinetic Assessment of the FIC CLDN18.2/4-1BB Bispecific Antibody in Rhesus Monkeys
    Wang, Jing
    Dong, Tiantian
    Gong, Xinjiang
    Li, Deli
    Sun, Joanne
    Luo, Yi
    Wu, Huazhang
    INTERNATIONAL JOURNAL OF TOXICOLOGY, 2024, 43 (03) : 291 - 300
  • [3] CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation
    Gao, Jing
    Wang, Zhengyi
    Jiang, Wenqing
    Zhang, Yanni
    Meng, Zhen
    Niu, Yanling
    Sheng, Zhen
    Chen, Chan
    Liu, Xuejun
    Chen, Xi
    Liu, Chanjuan
    Jia, Keren
    Zhang, Cheng
    Liao, Haiyan
    Jung, Jaeho
    Sung, Eunsil
    Chung, Hyejin
    Zhang, Jingwu Z.
    Zhu, Andrew X.
    Shen, Lin
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (06)
  • [4] First-in-human phase I/II safety and preliminary efficacy of PM1032, a bispecific antibody targeting CLDN18.2 and 4-1BB, in patients with advanced solid tumors.
    Guo, Ye
    Wu, Lihua
    Li, Yong
    Wen, Jinhua
    Xue, Junli
    Wang, Zhuoyi
    Li, Pu
    Zhao, Wei
    Liu, Jingfeng
    Rao, Xi
    Li, Qun
    Xue, Liqiong
    Ge, Xiaoxiao
    Lin, Fengjuan
    Tang, Wenbo
    Zhou, Jiuli
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [5] Claudin 18.2 X 4-1BB bispecific antibody induced potent tumor inhibition through tumor-specific 4-1BB activation
    Jiang, Wenqing
    Fang, Lei
    Wang, Zhengyi
    Guo, Taylor B.
    Park, Eunyoung
    Sung, Eunsil
    Jung, Jaeho
    CANCER RESEARCH, 2020, 80 (16)
  • [6] Discovery of a novel Claudin 6 X 4-1BB bispecific antibody with potent anti-tumor activity through conditional 4-1BB activation
    Li, Jian
    Jiang, Wenqing
    Liu, Yan
    Wang, Zhengyi
    Chen, Xi
    Guo, Taylor B.
    CANCER RESEARCH, 2022, 82 (12)
  • [7] A BIPARATOPIC ANTI-HER2 ANTIBODY ENABLED WITH CONDITIONAL 4-1BB AGONISM INDUCES POTENT ANTI-TUMOR EFFICACY
    Chen, Liandi
    Huang, Weifeng
    Miao, Xiaoniu
    Peng, Shaogang
    Wang, Chao
    Yan, Yao
    Chou, Chuan-Chu
    Tsun, Andy
    Luo, Yi
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A1372 - A1372
  • [8] DUAL-TARGETING OF 4-1BB AND OX40 WITH AN ADAPTIR™ BISPECIFIC ANTIBODY ENHANCES ANTI-TUMOR RESPONSES TO SOLID TUMOR
    Nelson, Michelle
    Miller, Robert
    Blahnik-Fagan, Gabriele
    Loh, Lauren
    Van Citters, Danielle
    Misher, Lynda
    Sprague, Megan
    Dasovich, Maria
    Barber, Irene
    Maggiora, Kathy
    Gruswitz, Franz
    Woodruff, Brian
    Huntington, Kelsey
    Guinn, Aelish
    Aguilar, Megan
    Daugherty, Mollie
    Haglin, Elizabeth
    Gross, Jane
    Pavlik, Peter
    McMahan, Catherine
    Bienvenue, David
    Hernandez-Hoyos, Gabriela
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A379 - A380
  • [9] Targeting 4-1BB in tumors enhances anti-tumor immune responses
    Weber, Amy Mackay
    Innamarato, Patrick
    Morse, Jennifer
    Kidd, Scott
    Asby, Sarah
    Sarnaik, Amod
    Pilon-Thomas, Shari
    CANCER RESEARCH, 2019, 79 (13)
  • [10] BH3120, PD-L1 X 4-1BB bispecific antibody, plus PD-1 antagonist results in synergistic anti-tumor efficacy with excellent safety profile
    Wang, Jun
    Wang, Jing
    Liu, Yang
    Xu, Jiangcheng
    Liu, Jiawang
    Lee, Kyoungwoo
    CANCER RESEARCH, 2024, 84 (06)
12345